Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment

dc.contributor.advisorDenti, Paolo
dc.contributor.authorAbdelwahab, Mahmoud Tareq
dc.date.accessioned2022-02-09T10:04:04Z
dc.date.available2022-02-09T10:04:04Z
dc.date.issued2021
dc.date.updated2022-02-08T08:22:38Z
dc.description.abstractTuberculosis continues to claim millions of lives each year despite enormous efforts to control the epidemic over the past century. It remains the leading cause of death worldwide from a curable infectious disease. Tuberculosis is a significant cause of maternal mortality and morbidity, but little is known about the effect of pregnancy on anti-TB drugs concentrations. A critical challenge to the global efforts to control the tuberculosis epidemic is the spreading of drug resistance to first-line tuberculosis drugs. The treatment of drug-resistant tuberculosis relies on both new anti-tuberculosis agents such as bedaquiline, delamanid, and pretomanid and repurposed drugs, such as linezolid and clofazimine. In this thesis, we employed nonlinear mixed-effects modelling to evaluate the pharmacokinetics of first-line tuberculosis drugs isoniazid, pyrazinamide, and ethambutol in pregnancy. We assessed the pharmacokinetics and pharmacodynamics of pretomanid, clofazimine, and linezolid in African tuberculosis patients. Reassuringly, we found no significant pregnancy effect on the exposure of these antituberculosis agents, thus confirming the suitability of current doses in pregnancy. For pretomanid, we found that in spite of exposure being reduced by 44% with rifampicin coadministration, the drug levels were within the efficacy range observed in previous trials, provided that pretomanid doses are administered with food. Clofazimine exposure was found to accumulate more slowly in women, an effect driven by sex-related differences in the proportion of body fat. We characterised the effect of clofazimine concentration on QT interval prolongation. We investigated alternative dosing regimen to optimise clofazimine treatment and suggested that a 2-week loading dose may support treatment shortening by safely enabling more rapid attainment of efficacy targets. For linezolid model, we characterised population pharmacokinetic parameters in African tuberculosis patients, assessed probability of target attainment and related toxicity following different doses administration. We showed that population modelling could maximize information from collected data, and have a significant impact on advancing patients care especially in places with limited resources.
dc.identifier.apacitationAbdelwahab, M. T. (2021). <i>Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment</i>. (). ,Faculty of Health Sciences ,Division of Clinical Pharmacology. Retrieved from http://hdl.handle.net/11427/35668en_ZA
dc.identifier.chicagocitationAbdelwahab, Mahmoud Tareq. <i>"Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment."</i> ., ,Faculty of Health Sciences ,Division of Clinical Pharmacology, 2021. http://hdl.handle.net/11427/35668en_ZA
dc.identifier.citationAbdelwahab, M.T. 2021. Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment. . ,Faculty of Health Sciences ,Division of Clinical Pharmacology. http://hdl.handle.net/11427/35668en_ZA
dc.identifier.ris TY - Doctoral Thesis AU - Abdelwahab, Mahmoud Tareq AB - Tuberculosis continues to claim millions of lives each year despite enormous efforts to control the epidemic over the past century. It remains the leading cause of death worldwide from a curable infectious disease. Tuberculosis is a significant cause of maternal mortality and morbidity, but little is known about the effect of pregnancy on anti-TB drugs concentrations. A critical challenge to the global efforts to control the tuberculosis epidemic is the spreading of drug resistance to first-line tuberculosis drugs. The treatment of drug-resistant tuberculosis relies on both new anti-tuberculosis agents such as bedaquiline, delamanid, and pretomanid and repurposed drugs, such as linezolid and clofazimine. In this thesis, we employed nonlinear mixed-effects modelling to evaluate the pharmacokinetics of first-line tuberculosis drugs isoniazid, pyrazinamide, and ethambutol in pregnancy. We assessed the pharmacokinetics and pharmacodynamics of pretomanid, clofazimine, and linezolid in African tuberculosis patients. Reassuringly, we found no significant pregnancy effect on the exposure of these antituberculosis agents, thus confirming the suitability of current doses in pregnancy. For pretomanid, we found that in spite of exposure being reduced by 44% with rifampicin coadministration, the drug levels were within the efficacy range observed in previous trials, provided that pretomanid doses are administered with food. Clofazimine exposure was found to accumulate more slowly in women, an effect driven by sex-related differences in the proportion of body fat. We characterised the effect of clofazimine concentration on QT interval prolongation. We investigated alternative dosing regimen to optimise clofazimine treatment and suggested that a 2-week loading dose may support treatment shortening by safely enabling more rapid attainment of efficacy targets. For linezolid model, we characterised population pharmacokinetic parameters in African tuberculosis patients, assessed probability of target attainment and related toxicity following different doses administration. We showed that population modelling could maximize information from collected data, and have a significant impact on advancing patients care especially in places with limited resources. DA - 2021_ DB - OpenUCT DP - University of Cape Town KW - Clinical Pharmacology LK - https://open.uct.ac.za PY - 2021 T1 - Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment TI - Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment UR - http://hdl.handle.net/11427/35668 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/35668
dc.identifier.vancouvercitationAbdelwahab MT. Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment. []. ,Faculty of Health Sciences ,Division of Clinical Pharmacology, 2021 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/35668en_ZA
dc.language.rfc3066eng
dc.publisher.departmentDivision of Clinical Pharmacology
dc.publisher.facultyFaculty of Health Sciences
dc.subjectClinical Pharmacology
dc.titlePopulation pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
dc.typeDoctoral Thesis
dc.type.qualificationlevelDoctoral
dc.type.qualificationlevelPhD
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
thesis_hsf_2021_abdelwahab mahmoud tareq.pdf
Size:
9.22 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Collections